Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 322,557 shares of the medical equipment provider’s stock after acquiring an additional 6,249 shares during the quarter. Envestnet Asset Management Inc. owned about 0.16% of Zimmer Biomet worth $29,420,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Chicago Partners Investment Group LLC lifted its holdings in shares of Zimmer Biomet by 3.3% during the second quarter. Chicago Partners Investment Group LLC now owns 3,865 shares of the medical equipment provider’s stock worth $376,000 after purchasing an additional 124 shares during the period. Private Trust Co. NA lifted its holdings in shares of Zimmer Biomet by 14.6% during the second quarter. Private Trust Co. NA now owns 1,073 shares of the medical equipment provider’s stock worth $98,000 after purchasing an additional 137 shares during the period. Brooklyn Investment Group lifted its holdings in shares of Zimmer Biomet by 45.9% during the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 145 shares during the period. IFP Advisors Inc lifted its holdings in shares of Zimmer Biomet by 8.3% during the second quarter. IFP Advisors Inc now owns 1,947 shares of the medical equipment provider’s stock worth $178,000 after purchasing an additional 149 shares during the period. Finally, Dakota Wealth Management lifted its holdings in shares of Zimmer Biomet by 1.8% during the first quarter. Dakota Wealth Management now owns 9,791 shares of the medical equipment provider’s stock worth $1,108,000 after purchasing an additional 171 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ZBH shares. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Redburn Partners set a $130.00 price target on Zimmer Biomet in a report on Thursday, September 18th. Canaccord Genuity Group reissued a “hold” rating and issued a $101.00 target price on shares of Zimmer Biomet in a report on Wednesday, October 22nd. Rothschild & Co Redburn started coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They set a “buy” rating and a $130.00 price target on the stock. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $111.94.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Trading Up 1.2%

NYSE:ZBH opened at $100.77 on Monday. The company has a market capitalization of $19.96 billion, a PE ratio of 24.52, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $114.72. The stock has a fifty day simple moving average of $101.45 and a 200-day simple moving average of $97.62.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. The firm had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.